Guidelines for HIV DIAGNOSIS and Monitoring of ANTIRETROVIRAL THERAPY
Guidelines for HIV DIAGNOSIS and Monitoring of ANTIRETROVIRAL THERAPY

WHO Project No: ICP BCT 001

World Health Organization
Regional Office for South-East Asia
New Delhi
July 2004
The technical material included in these guidelines has been compiled by Dr Rajesh Bhatia and Dr Jai P Narain of World Health Organization, Regional Office for South-East Asia. Various experts provided material for these guidelines which were reviewed by eminent scientists in this field. WHO acknowledges their contributions.

© World Health Organization 2004

This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced or translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes.

The views expressed in documents by named authors are solely the responsibility of those authors.
### Acronyms and Abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDS</td>
<td>Acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>ART</td>
<td>Antiretroviral therapy</td>
</tr>
<tr>
<td>ARV</td>
<td>Antiretroviral</td>
</tr>
<tr>
<td>CD4</td>
<td>T-lymphocyte CD4+</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>DOT</td>
<td>Directly observed therapy</td>
</tr>
<tr>
<td>FBC</td>
<td>Full blood count</td>
</tr>
<tr>
<td>Hgb</td>
<td>Haemoglobin</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>IDU</td>
<td>Injecting drug users</td>
</tr>
<tr>
<td>IFT</td>
<td>Immunofluorescence test</td>
</tr>
<tr>
<td>LA</td>
<td>Latex agglutination</td>
</tr>
<tr>
<td>MTCT</td>
<td>Mother-to-child transmission (of HIV)</td>
</tr>
<tr>
<td>NGO</td>
<td>Nongovernmental organization</td>
</tr>
<tr>
<td>NNRTI</td>
<td>Non-nucleoside reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NsRTI</td>
<td>Nucleoside analogue reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NRTI</td>
<td>Nucleotide analogue reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PI</td>
<td>Protease inhibitor</td>
</tr>
<tr>
<td>RT</td>
<td>Reverse transcriptase</td>
</tr>
<tr>
<td>RTV-OU</td>
<td>Ritonavir-boosted protease inhibitor</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TLC</td>
<td>Total lymphocyte count</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>Joint United Nations Programme on HIV/AIDS</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cells</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
CONTENTS

Preface v

1. HIV and Laboratories – An Overview ..............................................................1
2. Diagnosis of HIV Infection ...............................................................................6
3. Immunological Monitoring of Antiretroviral Therapy: CD4 counts ..........15
4. Virological Monitoring of ART .......................................................................22
5. Microbiological Monitoring of ART ...............................................................25
6. Laboratory Monitoring of Side-effects of ART .............................................29
7. Tuberculosis in HIV/AIDS .............................................................................33
8. New Technologies in HIV Diagnosis and ART Monitoring ......................36
9. Laboratory Infrastructure and Quality System ..........................................42

Suggested Further Reading....................................................................................55

Annexes

1. Suggested Sources of Availability of Laboratory Equipment and Supplies .....57
2. Collection and Storage of Clinical Specimens ............................................1
3. Procedures Carrying Potential Risks of HIV, HBV and other Bloodborne Agents .................................................................3
4. Contributors and Reviewers ............................................................................4
PREFACE

HIV/AIDS is among the greatest health crisis ever faced by humanity. Already this pandemic has killed 30 million people. Today, 38 million people are living with HIV. Each year, 3 million are dying of HIV/AIDS. However, most of these deaths could be prevented if they had access to antiretroviral therapy (ART).

In September 2003, WHO declared that failure to provide antiretroviral therapy to patients in developing countries a global public health emergency. Accordingly, WHO with UNAIDS and partners set a target of providing 3 million people in developing countries with antiretroviral treatment by the end of 2005 (the “3 by 5” initiative). While this is an interim target, long-term goal is of universal access to ART for all those who need it.

The primary objective of the antiretroviral therapy is to prolong the survival as well as improve the quality of life of the people living with HIV/AIDS. By bringing down the HIV viral load to sustained undetectable level, it is expected that ART will contribute also to HIV prevention.

Laboratory support is critical in all the areas of HIV diagnosis and management. Diagnosis of HIV infection cannot be established by any means other than serological tests by the laboratory. CD4 lymphocyte count is a prerequisite for the initiation of antiretroviral therapy and for monitoring treatment outcome. Both immunological and microbiological monitoring of antiretroviral therapy is therefore exclusively dependent on an efficient laboratory service.

While laboratory support to AIDS programmes is very important, the infrastructure, expertise and networking require strengthening in most countries of our Region.

In order to assist countries in building laboratory capacity, WHO has developed Regional Guidelines on HIV Diagnosis and Monitoring of Antiretroviral Therapy. WHO is committed to provide all possible technical support to the countries including for strengthening laboratory support. I sincerely hope that these Guidelines will be helpful to Member Countries in scaling up ART and responding to the rapidly evolving HIV/AIDS epidemic.

Samlee Plianbangchang, M.D., Dr.P.H.
Regional Director
1. HIV and Laboratories - An Overview

The human immunodeficiency virus (HIV) has changed the social, moral, economic and health fabric of the world in a short span. Today HIV/AIDS is the greatest health crisis faced by the global community. Till date, this pandemic has killed nearly 30 million people. More than 40 million are living with HIV, and to this pool, an additional 14,000 are added everyday. It is expected that, if not treated, 3 million people will die every year of HIV/AIDS. It is estimated that of the millions of people living with HIV/AIDS (PLWHA) in developing countries, 6 million people require antiretroviral therapy (ART). Most of these are in 34 high burden countries of Africa and Asia. Of these, only 400,000 are currently receiving ART.

![Figure 1.1 People Estimated to be living with HIV/AIDS, December 2003](image)
HIV/AIDS in the South-East Asia Region

More than 6 million people are living with HIV in the countries of the South-East Asia Region. India ranks as the country with the second largest number (5.1 million) of such people in the world and is next only to South Africa. Four countries (India, Thailand, Myanmar and Indonesia) are considered as high burden countries. Currently, only 50 000 people with HIV in the countries of the Region are receiving ART, which is 12% of the number of people who need it.

The understanding of the transmission of HIV has given rise to various interventions which can prevent the occurrence of new cases. Reduction of viral load by efficient antiretroviral therapy is also a powerful tool in the overall interventions against HIV. To accelerate global efforts in augmenting antiretroviral therapy WHO has launched an ambitious initiative called the “3 by 5” initiative.

“3 by 5” initiative

In September 2003, Dr Lee Jong-Wok, Director-General, WHO, declared the failure to provide antiretroviral therapy (ART) to patients in developing countries as a global health emergency and announced a new “3 by 5” initiative to provide ART to 3 million needy people in developing countries by the end of 2005, with the long-term goal of universal access to all those who need it. The basic principles of this initiative are: expanding access to ART and ensuring quality and adherence.

The Goal

To make the greatest possible contribution in prolonging survival and restoring the quality of life of individuals with HIV/AIDS, advancing towards the ultimate goal of universal access to antiretroviral therapy (ART) to those in need of care as a human right and within the context of a comprehensive response to HIV/AIDS.

The Target

- By the end of 2005, 3 million people in developing countries who need ART will be receiving effective ART.
- By the end of 2005, 400 000 people who need ART in the countries of the SEA Region will be receiving it.
Role of Laboratory in “3 by 5” Initiative

Areas in which laboratories will play a critical role in implementing the “3 by 5” initiative at the country level include detection of anti-HIV antibody as well as monitoring of ART.

Detection of HIV

The presence of HIV infection in individuals can be ascertained only through the use of laboratory tests on body fluids such as blood, plasma etc. WHO-UNAIDS have established an algorithm for the use of various tests for screening, surveillance and diagnostic purposes. These are being widely followed and their successful utilization has shown their utility.

Monitoring of ARV

Monitoring of patients on chemotherapy is essential in all infectious diseases. It is of greater importance in HIV because of the severity of illness, the potential of the virus to mutate and become resistant to drugs and the cost of treatment. Hence, laboratories are bound to play a critical role in the successful implementation of any ART programme. Various areas which need to be monitored are shown in Table 1.1: ART aims at reducing the viral load and augmenting the immune potential of the person.

<table>
<thead>
<tr>
<th>Monitoring</th>
<th>Laboratory area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virological</td>
<td>Viral load</td>
</tr>
<tr>
<td></td>
<td>Resistance to antiretroviral drugs</td>
</tr>
<tr>
<td>Immunological and Haematological</td>
<td>CD4 count</td>
</tr>
<tr>
<td></td>
<td>Total lymphocyte counts</td>
</tr>
<tr>
<td>Microbiological</td>
<td>Occurrence of new opportunistic infections</td>
</tr>
<tr>
<td></td>
<td>Recurrence of treated opportunistic infections</td>
</tr>
<tr>
<td></td>
<td>Antimicrobial susceptibility of bacterial pathogens</td>
</tr>
<tr>
<td></td>
<td>Reactivation of TB</td>
</tr>
<tr>
<td>Adverse drug reaction</td>
<td>Liver and kidney function tests</td>
</tr>
<tr>
<td></td>
<td>Haematological parameters</td>
</tr>
</tbody>
</table>

HIV-1 viral load measurement has also been found to be useful in monitoring treatment. It requires the establishment of a baseline plasma viral load before starting ART. The viral load in the case of successful ART becomes
undetectable in 4 to 6 months of therapy. It can be measured using a variety of commercial kits. A number of homebrew assays for virus load are in use. However, these need rigorous standardization and continued quality assurance which often is not possible in a developing country setting. The assessment of viral load, though possible, is a very expensive, complex and sophisticated procedure and hence not recommended by WHO under the “3 by 5” initiative.

Functions of laboratories

The laboratory techniques for supporting ART can be effectively applied for diagnosis and monitoring if a functional network of laboratories is created. Since many of the techniques are new, a network of laboratories with suggested functions at different levels is given in Table 1.2.

Table 1.2 Suggested networking of laboratories to support “3 by 5” initiative

<table>
<thead>
<tr>
<th>Peripheral</th>
<th>Intermediate</th>
<th>Central</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid anti-HIV antibody detection test</td>
<td>Peripheral lab +</td>
<td>Intermediate +</td>
</tr>
<tr>
<td>Haemoglobin estimation</td>
<td>Full blood count</td>
<td>CD4 count by flow cytometry</td>
</tr>
<tr>
<td>TB microscopy</td>
<td>Liver and renal function tests</td>
<td>EQAS for flow cytometry</td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>Opportunistic infections diagnosis (limited)</td>
<td>Viral load</td>
</tr>
<tr>
<td>Total lymphocytes count</td>
<td>CD4 count by flow or non-flow cytometry</td>
<td>Resistance studies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical chemistry markers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Opportunistic infections diagnosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evaluation of kits and technology</td>
</tr>
</tbody>
</table>

Support by WHO

“3 by 5” initiative is being implemented by WHO with globally coordinated activities. A strategic framework has been developed with the following five pillars:

- Global leadership, strong partnership and advocacy
- Urgent, sustained country support
• Simplified, standardized tools for delivering ART
• Effective, reliable supply of medicines and diagnostics
• Rapid identification and reapplication of new knowledge and successes

One of the pillars of this initiative is to ensure reliable supply of medicines and diagnostics. Realizing the inadequacies in the mechanisms at the country level to procure these, WHO has established AIDS Medicines and Diagnostic Services (AMDS) which will provide continuous technical support in procuring drugs and diagnostics.
2. Diagnosis of HIV Infection

In primary infection with human immunodeficiency virus, the virus in the blood can be demonstrated by nucleic acid-based test (PCR for pro-viral DNA and RT-PCR for viral RNA), p24 antigen testing or culture. Antibodies to HIV are detectable within four to six weeks of infection by commonly employed tests and in virtually all infected individuals within six months. Once antibodies appear in the blood, they persist for the lifetime (Fig 2.1).

The level of viraemia immediately after the acute primary HIV infection, or the viral load set point, is a predictive marker of HIV disease progression.

Figure 2.1 Laboratory markers during HIV-1 disease progression

Diagnosis of HIV infection can be carried out by detecting any of the following:
- Antibodies to HIV
• P24 HIV antigen
• HIV nucleic acid (RNA/DNA)
• Human Immunodeficiency Virus in clinical samples

The most commonly used test for the diagnosis of HIV infection is by serological tests detecting anti-HIV antibodies. It is economical, rapid and can be performed easily in most laboratories. HIV antibody assays are now commercially available in various formats.

**Detection of antibody to HIV**

ELISA is the most widely used technique for the detection of antibody to HIV. HIV antibody tests have been classified as first to fourth generation tests based on the principle used in the assays as well as the type of antigens used. The first generation tests used viral lysates as antigens and used to give numerous false positive reactions. The second generation tests used recombinant HIV proteins and/or synthetic peptides as antigens. The third generation kits used recombinant proteins/peptides since antigens were used in third generation assays. The fourth generation kits are based on simultaneous detection of HIV antibodies and immune complexes and have very high sensitivity and specificity.

ELISA techniques require an ELISA Washer and Reader and are suitable for use in laboratories where more than 30 samples are tested each time. Using antigens employed in the third generation ELISA systems, several rapid tests have been developed and are widely used. The commonly employed rapid anti-HIV tests are based on the principle of immunochromatography, dot immunoassay, or particle agglutination (e.g.- gelatin or latex). Rapid tests are visual tests that do not require the ELISA Reader. These tests are available in smaller test packs and each test has independent controls. Therefore, these are suitable for a laboratory that tests smaller sample numbers as well as for stand alone sample. They are technically simple to perform and most of them have sensitivity and specificity comparable to ELISA.

The cost of HIV antibody tests varies depending on the type of test used. ELISA-based tests cost between US$1-3 per test while rapid tests range from US$2-5 per test. The specimen of choice for anti-HIV antibody testing is serum or plasma. Assays for the detection of anti-HIV antibodies in whole blood, saliva/oral fluid, urine and dried blood spot have also been developed. However, these specimens (other than plasma or serum) should be subjected to testing only when their utility has been thoroughly validated.
Diagnosis of HIV infection in babies born to HIV-infected mothers cannot be established by conventional antibody tests. The presence of anti-HIV antibody in the newborn may not necessarily indicate primary infection. It may be due to passive transmission of anti-HIV antibody from mother to uninfected child. These maternal antibodies may persist even up to 18 months. Hence, diagnosis in children less than 18 months of age is possible only by the detection of HIV nucleic acids, viral culture, or detection of the p24 antigen.

**Specimen collection**

| Optimal time of specimen collection | Blood specimens can be collected at any convenient time. |
| Correct specimen type and method of collection | Whole blood or anticoagulated blood. Dried blood spots may also be collected. However, it is advisable to collect multiple spots for repeat assay or quality control. |
| Adequate quantity and appropriate number of specimens | Approximately 3-5 ml. An additional blood sample is required subsequently if the first sample gives a positive result. |

**Specimen transport and storage**

| Time between specimen collection and processing | Specimens should be transported and processed as soon as possible or within 24-48 hours. |
| Special considerations to minimize deterioration | If serum/plasma has been separated, it can be stored in a refrigerator for a week or in a freezer at –20° C or lower temperature for a longer period. |

**Criteria for rejection of sample**

| If specimen is haemolysed, turbid or has not been stored and transported properly, does not carry appropriate label, the container has leaked | Serum samples should be clear and straw coloured and sent in appropriate containers to the laboratory under cold conditions |
| Samples that are old/aged | Samples that are collected more than a week before and not stored in appropriate conditions should not be tested. |
Table 2.1: UNAIDS and WHO recommendations for HIV testing strategies according to test objective and prevalence of infection in the sample population

<table>
<thead>
<tr>
<th>Objective of testing</th>
<th>Prevalence of infection in the category to which the patient belongs (percentage)</th>
<th>Testing strategy applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening of blood and blood products</td>
<td>-</td>
<td>I</td>
</tr>
<tr>
<td>Surveillance</td>
<td>&gt;10</td>
<td>I</td>
</tr>
<tr>
<td>&lt;10</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>Diagnosis:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With clinical signs/symptoms</td>
<td>&gt;30</td>
<td>I</td>
</tr>
<tr>
<td>&lt;30</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>&gt;10</td>
<td>II</td>
</tr>
<tr>
<td>&lt;10</td>
<td>III</td>
<td></td>
</tr>
</tbody>
</table>

Figure 2.2 Schematic representation of the UNAIDS and WHO HIV testing strategies

1. Assay A1, A2 and A3 represent three different assays.
2. Such a result is not adequate for diagnostic purposes: use strategy II or III. Whatever the diagnosis, donations which were earlier reactive should not be used for transfusion or transplant.
3. Report: result may be reported.
4. For newly diagnosed individuals a positive result should be confirmed on a second specimen.
5. Test should be repeated on a second specimen taken after 14 days.
6. Result is considered negative in the absence of any risk of HIV infection.
The follow-up sample from patients with indeterminate result should be collected two weeks after the first sample collection. If the second sample also shows indeterminate result, it should be tested by a confirmatory assay (e.g., Western Blot). However, if the confirmatory test fails to resolve the serodiagnostics, follow-up testing should be undertaken at four weeks, three months, six months, and 12 months. After 12 months, such indeterminate results should be considered negative.

### Reporting Procedure

<table>
<thead>
<tr>
<th>Report</th>
<th>Negative – if initial/screening test shows non-reactive result.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive – if the sample shows reactive results concordantly by the three screening tests.</td>
</tr>
<tr>
<td>Indeterminate (equivocal)</td>
<td>Indeterminate (equivocal) - if the sample shows discordant results by the three screening tests, the follow up samples are required to retest at two weeks and at three, six and 12 months before the final status of the test results should be conveyed. If the status remains indeterminate after one year, the person is considered to be HIV antibody negative.</td>
</tr>
</tbody>
</table>

| Special considerations       | Pre-test, post-test counselling service should be provided and confidentiality should be maintained. |

### Selection of test kits

Selection of assays/reagents is a complex process that needs to be planned carefully. The overall performance of an assay/reagent depends upon a number of local factors. Quite often the manufacturer’s quoted sensitivity and specificity figures may not reflect the actual working figures. Therefore, selection of an assay/reagent needs to consider the testing needs of a centre and the resources available to meet those needs. Procurement systems may have a significant impact on the selection of kits. Stock control is vital, especially where continuity of supply cannot be guaranteed. Ongoing monitoring systems are essential to identify problems either with the assay/reagent or the laboratory.
A wide variety of test kits are now available for HIV diagnosis. The selection of appropriate test kits/assays/reagents is critical to ensure quality in laboratory services. Every country or laboratory must therefore define a policy for selection of the most appropriate kit. The steps that are involved in the selection of a test kit/reagent for a testing laboratory are:

- Careful consideration of various factors that influence the utilization of kits
- Evaluation and then selection of any kit
- Procurement and development of an appropriate distribution mechanism
- Ensuring stock control
- Monitoring of performance at users level

Factors that influence utilization and selection of kits

- Sensitivity and specificity of the system
- Intended use of assay/reagent
- Experience, qualification and competence of users and infrastructure available in the laboratory
- Ease of testing
- Type of sample and available volume
- Type of test controls provided
- Number of tests per kit
- Shelf life of kit
- Stability during transportation
- Storage and handling requirements during transport and their feasibility
- Resource availability
- Time scale of results
- Facilities and infrastructure for evaluation of kits

Sensitivity and specificity are undoubtedly key factors in the selection of a kit. Sensitivity is the ability of an assay to identify all infected individuals. The specificity of an assay, on the other hand, is the degree of false reactivity associated with an assay. Kits/assays with high sensitivity and specificity are desirable for use in HIV testing laboratories. A test with maximum sensitivity is desirable when it is to be used as a screening test, while high specificity is desirable for a test that is to be used as a confirmatory test.

Although sensitivity and specificity are crucial factors to be considered in the selection of a test kit/assay, other factors listed above are also equally important while choosing a kit. The purpose for which a test kit is being purchased is also a key factor that determines the choice. In the context of HIV this means whether the kit is being used for screening of blood, surveillance or diagnosis. In addition to this, competence of the staff who will perform the test as well as the infrastructure available in the laboratory are also important factors that need to be considered while choosing a kit. The ease of performance of an assay is also an important criteria used in the selection of kits. A number of rapid, simple and ELISA-based methods are available for the detection of HIV antibodies. If HIV results are required to be obtained within a short time and only a few samples need to be tested in a laboratory, rapid and simple HIV kits may be preferred over other assays. On the contrary, if a large number of samples are to be tested, assays such as ELISA may be preferred. The type of sample, volume of sample and whether dilution of sample is required are also factors that need to be considered while selecting the kits. These would depend on the location of the laboratory, the number of tests that are performed, need for trained personnel and the facilities that are available.

Reliable kit systems that provide internal controls are preferred. Similarly, for rapid tests, kits that provide a sample addition check are generally preferred. Kits with a long expiry date are preferred over those that have short expiry. Finally, the choice of a test kit/reagent would depend a great deal on the availability of financial resources, existing systems in place in
the laboratory and the time scale in which results are expected to be delivered.

**Evaluation and final selection of kit**

<table>
<thead>
<tr>
<th>Define specific requirements for assays/reagents for the country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepare a protocol for laboratory assessment</td>
</tr>
<tr>
<td>Collect all available relevant data pertaining to kits/reagents</td>
</tr>
<tr>
<td>Assess on paper each assay/reagent against specific requirements and list most suitable assays</td>
</tr>
<tr>
<td>Perform laboratory assessment of most suitable candidate kits</td>
</tr>
<tr>
<td>Evaluate results</td>
</tr>
<tr>
<td>Select assay/reagent</td>
</tr>
</tbody>
</table>

**Procurement**

Procurement of test kits/reagents depends on several factors which need to be considered. These factors in turn would depend on the logistics and practices that are prevalent in the laboratory such as mechanism of procurement of kits, specific requirements of laboratory and time frame for procurement.

**Monitoring subsequent performance**

Monitoring the performance of a reagent/kit is a continuous process which begins from the time of procurement until all the kits are used or reach expiry date. Each country should draw up a plan for periodic monitoring of reagents/kits at various testing levels in the country, much akin to those that are already existing for vaccines in many countries. It may be advisable to have periodic “post marketing surveillance” of the kits carried out in the
central laboratory which gets these kits for evaluation from various peripheral testing laboratories.

**Technical support from WHO**

Realizing the inadequacies in the mechanisms at the country level to procure reagents/kits, WHO has established a mechanism called AIDS Medicines and Diagnostic Services (AMDS) with the following features:

- **AMDS** is created to expand access to quality, effective anti-retroviral therapy (ART) by facilitating increased supply of drugs and diagnostics in developing countries.
- **AMDS** will provide to manufacturers information and forecasting about global demand/market.
- **AMDS** will provide to buyers sources, process and patents on drugs and diagnostics and assist them in obtaining the best prices for individual or pooled demand.
- **AMDS** will provide technical support to countries in improving their procurement mechanisms.
- **AMDS** will assist countries, NGOs and other Non-profit organizations.

**AMDS** has also created a pre-qualification project (PQP) which aims at ensuring quality, safety and efficacy of HIV/AIDS medicines and diagnostics. It assesses products voluntarily submitted by manufacturers and certifies their conformation to WHO standards. The approved drugs and diagnostics are shown in the public domain. Twenty-three HIV kits are available at present. CD4 and viral load kits are also being monitored. These services are managed by WHO in collaboration with UNICEF, UNAIDS, UNFPA and the World Bank. AMDS, however, will not provide free drugs or diagnostics to the countries. All the information pertaining to AMDS can be accessed from the WHO website.
3. Immunological Monitoring of Antiretroviral Therapy: CD4 counts

What are CD4 T Cells?

Cellular components of blood comprise red blood cells and white blood cells. Two populations of leucocytes constitute the latter - the granulocytes and non-granulocytes including the lymphocytes. Surface receptors of the lymphocytes provide identity to sub-populations of lymphocytes which differentiate into unique clusters. This property gives the subtypes of lymphocytes a nomenclature of clusters of differentiation followed by the number of the unique subtype (CD1, CD2, CD3, CD4.....). CD stands for cluster of differentiation; CD numbers are now used to identify cell surface antigens that can be distinguished by monoclonal antibodies. CD4 T cells are also known as helper cells and play a vital role in maintaining the integrity of the human immune system.

Importance of CD4 T cells

A primary target of HIV is CD4 T cells which are preferentially depleted during the course of the disease. The utility of CD4 T cell measurements involves clinical considerations for HIV disease classification and AIDS definition, assessment of prognosis, and the design of clinical trials. It is well recognized now that accurate and reliable enumeration of CD4 T cell counts is very crucial for monitoring the rate of progression to AIDS, both for initiating prophylaxis for opportunistic infections as well as monitoring the impact of antiretroviral therapy (ART).

Methods of enumeration of CD4 T cells

Immunofluorescence analysis by flow cytometry (FCM) is the gold standard for CD4 T cell measurements and also the first choice if a large throughput of samples is required. To obtain an absolute CD4 T cell count, two concepts are utilized:
Dual-platform (DP) approach

The DP approach uses two instruments to generate absolute CD4 T cell counts: a FCM for generating a percentage CD4 T cells among lymphocytes and a haematological analyzer to enumerate the absolute lymphocyte counts. An absolute CD4 T cell count is derived by multiplying %CD4 T cells by the absolute lymphocyte count. Examples of these DP FCM instruments include BD FACSCalibur/FASCScan/FACSort or Beckman-Coulter Epics XL.

Single-platform (SP) approach

This technique enables absolute CD T cell counts to be derived directly without the need for a haematological analyzer, i.e., the use of volumetric counting (Partec CyFlow), microfluorometry (Guava) and, most commonly, the addition of a known density of reference fluorescent beads to the sample (FACSCount).

Other Methods

For those countries and settings where infrastructure is not available for such FCM technologies, a number of accepted alternative assays have been developed and some are commercially available:

(1) Microscopic-bead assay, i.e., Dynabeads assay and Cytospheres.

Evaluations of these two assays were highly compatible with FCM technologies. These alternative assays, are however fairly labour intensive and thus less appropriate for a large number of samples. Moreover, qualified personnel are required for making accurate measurements.

(2) ELISA based assay, i.e., Immuno-alkaline phosphatase, TRAx, Zymmune and Capcellia

These assays have proven either too cumbersome or have an insufficient concordance with standard FCM. In addition, these assays need a well-trained technician for getting accurate results.

(3) Total lymphocyte counts

In case where CD4 testing cannot be assessed, the presence of a total lymphocyte count of 1200 cells/μL or below may be used as a substitute
indication for ARV treatment in symptomatic HIV-infected patients. While the total lymphocyte count correlates poorly with the CD4 T cell count in asymptomatic patients, in combination with clinical staging it is still a useful marker of prognosis and survival.

In the same patient all CD4 estimations must be done using the same technology to ensure comparability.

Utility of CD4 count in monitoring

According to the WHO recommendation, HIV-infected adults should start ARV therapy when infection has been confirmed and one of the following conditions is present (Table 3.1).

<table>
<thead>
<tr>
<th>WHO Stage</th>
<th>CD4 T Cell Counts</th>
<th>Total Lymphocyte Counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>Irrespective</td>
<td>Irrespective</td>
</tr>
<tr>
<td>III</td>
<td>&lt; 350 cells/uL</td>
<td>Irrespective</td>
</tr>
<tr>
<td>II</td>
<td>&lt; 200 cells/uL</td>
<td>&lt; 1200 cells/uL</td>
</tr>
<tr>
<td>I</td>
<td>&lt; 200 cells/uL</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

* It should be noted that in HIV-related symptoms (Stage II, III), a total lymphocyte count of 1200 cells/uL can be substituted for the CD4 T cell count when the latter is not available. However, asymptomatic HIV-infected patients (Stage I) need not be treated because the total lymphocyte count correlates poorly with the CD4 T cell count in asymptomatic patients.

Sample guidelines

Blood samples are collected by venipuncture into K$_3$EDTA-containing tubes, mixed well and processed within the time-frame which should not exceed 30 hours. Blood samples should preferably be collected within a fixed time in the day so as to avoid diurnal variations. Blood sample that is not suitable is rejected (for example, blood sample that cannot be performed within the time-frame, or if blood sample is hemolyzed or frozen or clotted or without proper labelling).
Suggestions for testing at different levels

Samples can be processed at different clinical laboratory levels and different volume of samples/day. The choice could also depend on the availability of FCM it, if not, simple total lymphocyte count or one of the alternative light microscope staining and counting assays could be used (Table 3.2).

<table>
<thead>
<tr>
<th>Laboratory Level</th>
<th>Number of Samples/day</th>
<th>Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral</td>
<td>1-5</td>
<td>Total lymphocyte count</td>
</tr>
<tr>
<td></td>
<td>1-5</td>
<td>Dynabeads or Cytospheres</td>
</tr>
<tr>
<td></td>
<td>1-5</td>
<td>FCM CD4 testing</td>
</tr>
<tr>
<td>Intermediate</td>
<td>5-20</td>
<td>FCM CD4 testing</td>
</tr>
<tr>
<td></td>
<td>5-20</td>
<td>Transfix*/Central lab</td>
</tr>
<tr>
<td>Central</td>
<td>&gt; 20</td>
<td>FCM CD4 testing</td>
</tr>
</tbody>
</table>

* Transfix is a whole blood stabilizing reagent. When Transfix is added to fresh blood, the sample retains its integrity for almost one week. The use of Transfix is therefore suitable to increase the catchment area of central laboratories.

Gold standard for CD4 count: Flow Cytometry

Principle

Flow cytometer operates by introducing cells stained with fluorescence conjugated antibody or absorption dyes in a fluid stream under a slight pressure to pass through a nozzle into the beam of light, usually generated by a laser. Light that is scattered and emitted by cells is then separated into constituent wavelengths by a series of optical filters and mirrors. This separated optical light falls on individual photodetectors and then is translated into electrical pulse, or analog signals, proportional to the amount of incident light detected by the detectors. Each analog signal is finally converted into a digital signal. The magnitude of digital signals is then processed by the data processing and analysis unit. The numbers are proportional to the amount of light emitted from, or scattered by, individual stained cells.
**Samples**

Cells to be measured must be suspended in a liquid. So, ideally, this is simple for whole blood. Anticoagulant blood is stained with appropriate monoclonal antibody that binds to the specific antigens, i.e. CD4 that are to be measured. Normally, the monoclonal antibody is directly conjugated with fluorochrome.

**Advantages and disadvantages**

Table 3.3  **Advantages and disadvantages of using flow cytometer for CD4 testing**

<table>
<thead>
<tr>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference method</td>
<td>Expensive instrument</td>
</tr>
<tr>
<td>High reliability</td>
<td>Expensive reagents</td>
</tr>
<tr>
<td>High accuracy, precision and reproducibility</td>
<td>Expensive maintenance</td>
</tr>
<tr>
<td>Handling large number of samples</td>
<td>Need well-trained technician</td>
</tr>
</tbody>
</table>

**Cost**

At present, the cost of CD4 testing varies from country to country and ranges between US$12-US$30. However, the recent development of a simplified PanLeucogating method together with the use of generic monoclonal antibody reagents drastically cut the cost of CD4 test by more than one-fourth.

**Quality system**

Several sets of guidelines addressing quality control of CD4 T cell enumeration have been developed. It is important that accurate daily internal quality control and proficiency test or external quality assurance programmes be employed to ensure the reliability and value of CD4 T cell data. However, participation in most of the current international external quality assurance programme requires a substantial amount of funding to cover the cost of participation fees and carriages. There are free external quality assurance programmes, in spite of their irregular schedules, they are useful and cost saving.
Reporting result

All data are reported in terms of percentages and absolute counts of CD4 T cells, or %CD4 T lymphocytes with a short description of what CD4 means (for example, CD4 T cells are T-helper cells) when these are available. It should be noted that the absolute counts are used in adult HIV-infected patients, whereas only the percentages are used in paediatric HIV-infected patients. In the report, the mean and reference of both percentage and absolute CD4 T cells (normal ranges) should also be given. Each clinical laboratory should validate normal ranges.

Total Lymphocyte Counts

Principle

The total lymphocyte counts are easily performed by automated haematology cell counters on aspirated blood samples appropriately diluted with a solution (e.g., acid or detergent) that lyses the red blood cells but preserves leucocyte integrity. A typical automated haematology cell counter performs white blood cell counts by either impedance or light-scattering technology or both. Cells in suspension are made to flow through a small orifice across which an electric current is flowing as in impedance technology. As a cell enters the orifice, the flow current is reduced. Electronic circuits detect the decrease in current and thus the presence of the cell. In a light-scattering haematology cell counter, cells flow through a light beam rather than through an orifice. Different cell types intercepted by light will show different patterns based on the size and shape of the cells. In this way, the device can count the number of cells per second of flowing cells through the orifice or light beam, and because the volume flow rate can be measured one can thus determine the number of white blood cells per uL and or total lymphocyte count per uL of blood sample.

Samples

Collect blood samples by venipuncture into tubes containing K3EDTA anticoagulant. Mix the blood well to prevent clotting. Aliquot appropriate amount of blood into tube containing lysing buffer (e.g. an acid buffer or a detergent) to lyse red blood cells. The lysed whole blood samples are
processed and analysed for their white blood cell count and total lymphocyte count by using haematology cell counter.

Advantages and disadvantages

Table 3.4 Advantages and disadvantages of using total lymphocyte count for ARV therapy

<table>
<thead>
<tr>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inexpensive unit cost</td>
<td>High variation (CV up to 15%)</td>
</tr>
<tr>
<td>Simple and commonly available test</td>
<td>No EQAS</td>
</tr>
<tr>
<td>Less complicated instruments compared to FCM</td>
<td>Fault results due to nucleated red blood cells, platelet aggregation and nonlysed red blood cells.</td>
</tr>
</tbody>
</table>

Cost

The cost of total lymphocyte counts is cheap compared to CD4 testing, and it is varies from country to country but is around US$ 1.0-US$ 2.0

Quality system

At present no external quality assurance on white blood cell counting is available. Only internal quality control supplied from each manufacturer is recommended. It is important that accurate daily internal quality control and proficiency test, if applicable, be employed to ensure reliability and value of total lymphocyte count data.

Reporting result

In haematology cell counter the total lymphocyte count is calculated from direct measurement of lymphocyte count, and expressed as cells x 10^3/uL. Normal value for total lymphocyte count is 2.6 x 10^3/uL (range 1.0-4.9 x 10^3/uL). Normal ranges should be validated by each clinical laboratory.
4. Virological Monitoring of ART

Viral Load Testing

HIV1 viral load measurement is useful for monitoring treatment. A baseline plasma viral load is established before starting ART. Periodic monitoring is essential. It is predicted that with successful therapy a fall of 1.5 to 2 log in plasma viral load occurs within 4-6 weeks. With successful ART, it should become undetectable in 4 to 6 months of therapy.

Viral load is measured using a variety of commercial kits. The Amplicor HIV-1 Monitor test, version 1.5 is used widely. The assay uses gag specific primers for the highly conserved region. The lower limit of detection is 400 RNA copies/ml and the upper limit is 750 000 RNA copies/ml. The Amplicor ultra sensitive kit detects down to 50 copies/ml of plasma.

A real time PCR is being tested in some laboratories. The cheaper cost of the test and the advantage of avoiding batch testing are some of the plus points. The test uses primers and probe set specific for the LTR region of the HIV genome, which is conserved across subtypes. The primers need to be selected carefully as some subtypes may be estimated in relatively lower copy numbers with some of the primers. The lower limit of detection is in the range 50 IU/mL. The virological assays are useful tools in monitoring for the emergence of resistance in HIV against antiretroviral drugs.

HIV Drug Resistance Assays

The increase in the use of ART is expected to lead to the emergence of drug-resistant mutants of HIV1. This has been the experience from other parts of the world. The inherent mutability of the reverse transcriptase (RT) gene of HIV allows for drug resistance to emerge under selection pressure. The protease gene also undergoes mutations, which manifest as failure to respond to protease inhibitors.
A survey of drug resistance of indigenous HIV strains is essential to ascertain the usefulness of the antiretrovirals especially, in public health programmes. Drug resistance should be suspected if the plasma viral load does not show a greater than 1 log fall within 8 weeks of therapy.

The examination of plasma RNA for resistant HIV strains indicates circulating mutants, if any, including emergent polymorphisms. The proviral DNA testing reveals mutants that have emerged in the individuals about a year ahead and has slowly replaced the native wild type derived provirus.

Two types of antiretroviral drug resistance assays exist today are: Phenotypic Assays, and Genotypic Assays

**Phenotypic assays**

The phenotypic assays amplify the RT and protease genes from the predominant quasispecies in the patient’s plasma virus RNA or proviral DNA. These amplicons are then inserted into the laboratory virus lacking the genes. The hybrid virus is then propagated in cell cultures and its ability to propagate in the presence of varying concentrations of drug is measured. Results are expressed as the concentrations of drug required to inhibit 50% of growth (IC\textsubscript{50}) are relative to a wild type control strain. This work can be carried out only in laboratories with recommended bio-safety measures in place.

**Genotypic Assays**

The genotypic assays detect changes in the sequence of the relevant HIV1 gene. This measures resistance by detecting mutations in the HIV1 genome that leads to one or more specific amino acid substitutions in the HIV1 reverse transcriptase or protease enzymes. These specific changes cause drug resistance. Viral RNA from plasma or proviral DNA can be used for testing. The amplified products are then sequenced. The sequences are analysed using the special software such as Stanford University Online software (http://hivdb.stanford.edu/), Los Alamos National Laboratories HIV Sequence Database (hiv-web.lanl.gov), http://www.hivresistanceweb.com/request/pda.shtml, etc.,
Table 4.1 Advantages and disadvantages of genotypic assays over phenotypic assays

<table>
<thead>
<tr>
<th>Category</th>
<th>Genotypic assay</th>
<th>Phenotypic assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advantages</td>
<td>• Less expensive than phenotypic assays</td>
<td>• Interpretation similar to susceptibility testing of bacteria</td>
</tr>
<tr>
<td></td>
<td>• Short turn around time (&lt; 1 week)</td>
<td>• Assesses the total effect of mutational changes</td>
</tr>
<tr>
<td></td>
<td>• May detect presence of resistance mutations before they have resulted in</td>
<td>• Good reproducibility</td>
</tr>
<tr>
<td></td>
<td>phenotypic resistance</td>
<td>• The threshold to define susceptibility is arbitrary</td>
</tr>
<tr>
<td></td>
<td>• Can be standardized in a BSL-2 facility laboratory</td>
<td></td>
</tr>
<tr>
<td>Disadvantages</td>
<td>• Interpretation requires knowledge of mutational changes</td>
<td>• Very expensive to set up and run</td>
</tr>
<tr>
<td></td>
<td>• May show discrepancy with phenotypic assay</td>
<td>• Turn around time is more (3 weeks) than that of genotypic assays.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Slower to show resistance relative to genotypic assays</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• To be handled only in a BSL-3 level laboratory</td>
</tr>
</tbody>
</table>
5. Microbiological Monitoring of ART

Morbidity and mortality in HIV disease is due to the occurrence of life-threatening opportunistic infections (OIs) during the natural course of the disease. These are the direct consequence of a decline in CD4 count. A wide variety of opportunistic infections (Table 5.1) are encountered in patients with AIDS which are caused by various microorganisms. Very often these represent reactivation of organisms that have been dormant in the host for several years. The incidence of these diseases increases as the patient's CD4 count declines. The pattern/repertoire of opportunistic infections may vary in different geographic areas. The knowledge of important OIs specific for particular areas/countries is useful for correct diagnosis and management of OIs.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Pathogen</th>
<th>Infection type</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacterial</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuberculosis and non-tuberculous infections</td>
<td>Mycobacterium tuberculosis</td>
<td>Pulmonary or meningeal or other extra-pulmonary or systemic</td>
</tr>
<tr>
<td></td>
<td>Mycobacterium avium complex</td>
<td></td>
</tr>
<tr>
<td>Salmonellosis</td>
<td>Salmonella sp.</td>
<td>Typhoid fever or diarrhoea</td>
</tr>
<tr>
<td>Bacterial pneumonia</td>
<td>Streptococcus pneumoniae, Nocardia sp., Pseudomonas aeruginosa</td>
<td>Pulmonary infection</td>
</tr>
<tr>
<td><strong>Fungal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candidiasis</td>
<td>Candida albicans</td>
<td>Oral thrush or vulvovaginitis</td>
</tr>
<tr>
<td>Cryptococcosis</td>
<td>Cryptococcus neoformans</td>
<td>Meningoencephalitis, or pulmonary or systemic disease</td>
</tr>
<tr>
<td>Aspergillosis</td>
<td>Aspergillus sp.</td>
<td>Pulmonary disease or sinusitis</td>
</tr>
<tr>
<td>Disease</td>
<td>Pathogen</td>
<td>Infection type</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Histoplasmosis</td>
<td>Histoplasma capsulatum</td>
<td>Pulmonary disease or disseminated</td>
</tr>
<tr>
<td>Penicilliosis</td>
<td>Penicilium marneffei</td>
<td>Pneumonitis or disseminated disease</td>
</tr>
</tbody>
</table>

**Parasitic**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Pathogen</th>
<th>Infection type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumocystis carinii pneumonia</td>
<td>Pneumocystis carinii</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>Toxoplasmosis</td>
<td>Toxoplasma gondii</td>
<td>Encephalitis</td>
</tr>
<tr>
<td>Cryptosporidiosis</td>
<td>Cryptosporidium parvum</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Isosporosis</td>
<td>Isospora belli</td>
<td>Diarrhoea</td>
</tr>
</tbody>
</table>

**Viral**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Pathogen</th>
<th>Infection type</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMV infection</td>
<td>Cytomegalovirus(CMV)</td>
<td>Retinitis or encephalitis or esophagitis or colitis</td>
</tr>
<tr>
<td>Herpes</td>
<td>Herpes Simplex virus(HSV)</td>
<td>Chronic ulcer or bronchitis or pneumonitis, or esophagitis</td>
</tr>
</tbody>
</table>

**Utility of microbiological monitoring**

Natural history studies from India by shows that persons with a CD4 lymphocyte count of < 200 cells/uL are 19 times more likely to die than those with a CD4 cell count of > 350 cells/uL. Most of the diagnosed individuals have more than one opportunistic infections. Patients who had more than 1 opportunistic infections were 2.6 times more likely to die than those who did not have an opportunistic infection.

**Diagnosis of opportunistic infections**

Infrastructure facilities should be established based on the level of set-up required (Table 5.2). Although intermediate laboratories have sufficient facilities, further identifications and confirmations may be done by central laboratory. The flow of specimens should be worked out from low to higher
level and the flow of technical, scientific information and QA/QC procedures should be higher to lower levels.

Table 5.2  **Suggested laboratory diagnostic procedures to be performed at different levels**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Peripheral</th>
<th>Intermediate</th>
<th>Central</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuberculosis and non-tuberculous infections</td>
<td>AFB smear</td>
<td>AFB smear, Culture</td>
<td>AFB smear, Culture and sensitivity, PCR</td>
</tr>
<tr>
<td>Salmonellosis</td>
<td>-</td>
<td>Culture and sensitivity</td>
<td>Culture and sensitivity</td>
</tr>
<tr>
<td>Bacterial Pneumonia</td>
<td>-</td>
<td>Culture and sensitivity</td>
<td>Culture and sensitivity</td>
</tr>
<tr>
<td>Candidiasis</td>
<td>Gram’s staining</td>
<td>Gram’s staining</td>
<td>Culture and sensitivity</td>
</tr>
<tr>
<td>Cryptococcosis</td>
<td>Negative staining</td>
<td>Culture</td>
<td>Culture</td>
</tr>
<tr>
<td>Aspergillosis</td>
<td>10% KOH mount</td>
<td>Culture</td>
<td>Culture</td>
</tr>
<tr>
<td>Histoplasmosis</td>
<td>10% KOH mount</td>
<td>Culture</td>
<td>Culture</td>
</tr>
<tr>
<td>Peniciliosis</td>
<td>10% KOH mount</td>
<td>Culture</td>
<td>Culture</td>
</tr>
<tr>
<td>PCP</td>
<td>-</td>
<td>-</td>
<td>IFT</td>
</tr>
<tr>
<td>Toxoplasmosis</td>
<td>-</td>
<td>LA Test</td>
<td>IFT</td>
</tr>
<tr>
<td>Cryptosporidiosis</td>
<td>-</td>
<td>Wet mount, Modified acid-fast staining</td>
<td>Modified acid-fast staining, IFT</td>
</tr>
<tr>
<td>Isosporosis</td>
<td>-</td>
<td>Wet mount, Modified Acid-Fast staining</td>
<td>Modified Acid-Fast staining, IFT</td>
</tr>
<tr>
<td>CMV infection</td>
<td>-</td>
<td>-</td>
<td>IFT, Cell culture, PCR</td>
</tr>
<tr>
<td>Herpes</td>
<td>-</td>
<td>-</td>
<td>Cell culture, PCR, IFT</td>
</tr>
</tbody>
</table>

IFT : Immunoflourescent technique, LA : Latex agglutination
Role of central laboratory in sharing data

The microbiological monitoring of opportunistic infections will require complementary activities of various partners in the laboratory network. The central laboratory (or National Reference Laboratories for the particular organism) shall act as the apical laboratory and collate data from other laboratories to feed them into the national programme. The central laboratory, in addition, shall train laboratory staff and assure appropriate management including safe collection and processing of bio-specimens; act as country focal point for national coordination if there is a problem in identification and confirmation; act as technical resource centre; assure and/or assess quality in subordinate laboratories; prepare relevant guidelines and their distribution to other laboratories; maintain a repository of the isolates and reference strains and monitor the resistance in isolates against the specific antimicrobial agents.
6. Laboratory Monitoring of Side-effects of ART

Toxicity is related to the inability to tolerate the side-effects of medications and to significant organ dysfunction that may result because of toxicity. All the available anti-retroviral agents have potential toxicities (Table 6.1). Careful monitoring of patients by laboratory investigations play a major role in better clinical management. Toxicity should be monitored clinically based on patient reports and physical examination, supplemented by a limited number of laboratory tests depending on the symptoms that arise and the specific combination regimen that is used.

Table 6.1  **Adverse drug reactions of individual antiretroviral agents**

<table>
<thead>
<tr>
<th>Agent</th>
<th>Affects quality of life</th>
<th>Serious, may require intervention</th>
<th>Serious and life-threatening</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NRTI (Nucleoside Reverse Transcriptase Inhibitor)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir (ABC)</td>
<td>Headache</td>
<td></td>
<td>Systemic hypersensitivity reaction</td>
</tr>
<tr>
<td>Didanosine (DDI)</td>
<td>Diarrhoea, peripheral neuropathy</td>
<td>Pancreatitis</td>
<td>Fatal pancreatitis with lactic acidosis</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
<td>Nausea, vomiting</td>
<td>Pancreatitis in children; increased anemia</td>
<td></td>
</tr>
<tr>
<td>Stavudine (D4T)</td>
<td>Lipoatrophy, peripheral neuropathy</td>
<td>Hepatotoxicity</td>
<td>Rapidly ascending neuromuscular weakness associated with lactic acidosis</td>
</tr>
<tr>
<td>Tenofovir (TDF)</td>
<td>Diarrhoea, headache, asthenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zalcitabine (DDC)</td>
<td>Aphthous ulcer, peripheral neuropathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zidovudine (AZT)</td>
<td>Headache; nausea, vomiting; myalgia</td>
<td>Neutropenia; megaloblastic anemia</td>
<td>Severe anemia</td>
</tr>
</tbody>
</table>
### NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Affects quality of life</th>
<th>Serious, may require intervention</th>
<th>Serious and life-threatening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delavirdine (DLV)</td>
<td>Nausea, vomiting</td>
<td>Skin rash, liver enzyme elevation</td>
<td></td>
</tr>
<tr>
<td>Efavirenz (EFV)</td>
<td>Insomnia, somnolence, abnormal dreams, dizziness, decreased concentration, drowsiness</td>
<td>Depression, suicidal ideation, hallucination, psychosis, skin rash, liver enzyme elevation</td>
<td></td>
</tr>
<tr>
<td>Nevirapine (NVP)</td>
<td>Skin rash, liver enzyme elevation</td>
<td>Stevens-Johnson syndrome, fulminant hepatic necrosis</td>
<td></td>
</tr>
</tbody>
</table>

### PI (Protease inhibitor)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Affects quality of life</th>
<th>Serious, may require intervention</th>
<th>Serious and life-threatening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amprenavir (APV)</td>
<td>Nausea, vomiting, abdominal pain</td>
<td>Skin rash</td>
<td></td>
</tr>
<tr>
<td>Indinavir (IDV)</td>
<td>Requires adequate daily fluid intake to prevent crystalluria; paronychia; hair thinningloss</td>
<td>Nephrolithiasis, renal failure</td>
<td>Rarely hemolytic anemia</td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>Diarrhoea, nausea, vomiting, perioral paresthesia, taste perversion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nelfinavir (NFV)</td>
<td>Diarrhoea</td>
<td>Diarrhea may lead to severe dehydration</td>
<td></td>
</tr>
<tr>
<td>Ritonavir (RTV)</td>
<td>Nausea, vomiting; diarrhea, abdominal pain, anorexia, perioral paresthesia, taste perversion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saquinavir (SQV)</td>
<td>Nausea, vomiting, abdominal pain</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Monitoring of Adverse Reactions

Monitoring toxicities of the drug can be done clinically based on patient reporting and physical examination. However, inclusion of limited laboratory investigations in the ARV monitoring will determine the severity of the toxicity and this will help physician to change the dose and specific drug combination in regimen. When the toxicity is related to an identifiable drug in the regimen,
the offending drug can be replaced with another drug that does not have the same side effect.

**Monitoring of ART**

The different level testing capabilities and type of specimen to be collected for monitoring of ART toxicity are described in Table 6.2.

Table 6.2 **Suggested testing capabilities at different levels**

<table>
<thead>
<tr>
<th>Lab tests</th>
<th>Level 1: Peripheral</th>
<th>Level 2: Intermediate</th>
<th>Level 3: Central</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin</td>
<td>Hemoglobinometer¹</td>
<td>Haematology Analyser²</td>
<td>Haematology Analyser</td>
</tr>
<tr>
<td>Total and differential cell count</td>
<td>Microscopic - Manual</td>
<td>Haematology Analyser</td>
<td>Haematology Analyser</td>
</tr>
<tr>
<td>Complete blood count</td>
<td>As above</td>
<td>Haematology Analyser</td>
<td>Haematology Analyser</td>
</tr>
<tr>
<td>Liver and renal function markers</td>
<td>-</td>
<td>Medium throughput autoanalyser³</td>
<td>High Throughput Autoanalyser⁵</td>
</tr>
<tr>
<td>Complete clinical chemistry markers</td>
<td>-</td>
<td>Medium throughput autoanalyser and Ion selective electrode⁴</td>
<td>High throughput autoanalyser and Ion selective electrode</td>
</tr>
<tr>
<td>including serum electrolytes.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy testing</td>
<td>Rapid test</td>
<td>Rapid test</td>
<td>Rapid test</td>
</tr>
</tbody>
</table>

Approximate cost of the instruments: $10,000¹, $10,000², $24,000³, $40,000⁴, $80,000⁵.

- Patients with hepatitis B and C should be monitored more closely for liver toxicity. Hepatitis B (HBV) and hepatitis C (HCV) testing may be undertaken in the particular community, where the prevalence is high.
- The critical values (abnormal values) of the laboratory results should be reported only after consultation with the treating physician.

**Role of Central Laboratories**

The laboratory-based monitoring of adverse drug reactions will require complementary activities of various partners in the laboratory network. The central laboratory (or National Reference Laboratories for the particular parameter) shall act as the apical laboratory and collate data from other
laboratories to feed them into the national programme. The central laboratory, in addition, shall train laboratory staff and assure appropriate management including safe collection and processing of bio-specimens; act as country focal point for national coordination; act as a technical resource centre; assure and/or assess quality in subordinate laboratories; prepare relevant guidelines and their distribution to other laboratories; help other laboratories by providing the information regarding the selection of reagent make and methods of the test; and establish and maintain normal ranges for Haematology and Chemistries.
7. Tuberculosis in HIV/AIDS

The South-East Asia Region bears 40% of the global TB burden and ranks second after sub-Saharan Africa in the estimated number of people living with HIV/AIDS. Each year, nearly 3 million cases of TB and 750 000 TB deaths are estimated to occur in the Region. Of the estimated 6 million adults living with HIV in the Region, about half are likely to be infected with TB. The extent to which HIV will contribute to the TB epidemic depends on the degree of overlap between the population groups infected with TB and those with HIV.

Pulmonary tuberculosis accounts for more than 90% of total tuberculosis manifestation in HIV patients. Before the AIDS pandemic, non-tuberculosis mycobacteria rarely caused serious illness, even in the immunocompromised individuals. The prolonged immunosuppression of the cell-mediated immune system caused by HIV provided the opportunity for these relatively avirulent organisms (non-tubercular mycobacteria) to cause disease.

Laboratory Diagnosis

Tuberculosis in HIV-infected persons may occur with different manifestations. All these forms of tuberculosis, except when cavitations occur in pulmonary tuberculosis, are paucibacillary in nature. Depending upon the form of disease manifestation, several specimens such as sputum and/or gastric lavage, bronchoalveolar lavage, (BAL), lymph nodes and other biopsy specimens, pus, ascetic fluid, pleural and cerebrospinal fluid should be examined. If delay is anticipated, biopsy specimens may be collected in a suitable transport medium for sending them to the laboratory.

Collection of Sputum

For diagnosis of tuberculosis, three specimens of sputum are to be examined (spot morning-spot) over a period of two days. Specimens are to be collected in sterile universal containers, and should have a fixed label for noting patient’s details on the side of the container.
Specimen collection

- Aerosol free container (Sputum cup with a lid or Mc Cartney bottle)

Adequate quantity and appropriate number of specimens

- Ideally, a minimum volume of 5 ml
- Three consecutive sputum specimens should be collected

Specimen transport and storage

- Sterile leak-proof container in a sealed plastic bag.
- To be transported within three days for culture; if delay is anticipated, add equal volume of 1% CPC

Specimen staining

- Ziehl-Neelsen staining
  Note: heat-fixing may not kill all Mycobacterium species. Slides should be handled carefully.

Culture and investigation

- Specimen processing
- Sputum: Modification petroff’s method for digestion and decontamination.
- Other samples: Direct inoculation for aseptic specimens.
- Mild acid or other standard pretreatment procedure
- Inoculation on Lowenstein –Jensen media or Middlebrook 7 H9 or Kirchner’s medium.
- Examination for eight consecutive week or until it becomes positive or contaminated.

**Sputum Smear Microscopy**

Microscopy of sputum is of great value in the detection of open or infectious cases of tuberculosis. The establishment of a good sputum microscopy service is of prime importance in developing countries for the detection and treatment of open cases.

Smears are stained by the Ziehl-Neelsen (ZN) method, or by one of its various modifications. Grading of the positive smears gives a broad indication of the severity of the disease and the response to therapy.

The laboratory number is written, with a diamond marker, on one edge of a new, clean, grease-free and unscratched slide’s using a broomstick or a wire loop (5mm diameter), a purulent portion of the sputum is placed on the slide and spread evenly to give a smear of approximately 3 x 2 cm. The smear is allowed to air-dry and fixed by pressing over a flame 3-5 times for 3-4
seconds each time. It is then stained with carbol fuchsin decolorized with 25% sulphuric acid and counter-stained with methylene blue and dried using standard staining protocol. A drop of cedarwood oil or liquid paraffin is placed on the slide without touching the smear and examined under an oil-immersion objective for at least 10 minutes.

Sputum Culture

Sputum culture for mycobacteria requires more sophisticated laboratory facilities with biosafety level 2 or 3. Bio-safety hoods and arrangements for safe disposal of culture media and sputum samples need to be available. The standard culture technique for mycobacteria is to decontaminate by modified Petroff’s method, where sputum is decontaminated with 4% NaOH and then inoculated on to Lowenstein-Jensen slopes. The incubated cultures are examined once a week for 8 consecutive weeks or until they become positive or contaminated.

Identification

The identification of strains isolated as belonging to M. tuberculosis complex or Non-tuberculous mycobacteria (NTM) can be ascertained by performing a few simple tests, i.e. susceptibility to p-nitrobenzoic acid (PNB), niacin production test, catalase activity requirement and the morphological appearance. Important differences between Mycobacterium tuberculosis and NTM are shown in Table 7.1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>M.tuberculosis</th>
<th>NTM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth rate</td>
<td>Slow grower</td>
<td>Slow/Rapid grower</td>
</tr>
<tr>
<td>Temperature</td>
<td>37°C</td>
<td>25 - 45°C</td>
</tr>
<tr>
<td>Colony morphology</td>
<td>Dry rough</td>
<td>Dry</td>
</tr>
<tr>
<td>Colony on solid media</td>
<td>Eugonic</td>
<td>Dysgonic</td>
</tr>
<tr>
<td>Colour of colony</td>
<td>Buff</td>
<td>Yellow, orange or creamy</td>
</tr>
<tr>
<td>Emulsification</td>
<td>Difficult</td>
<td>Easy</td>
</tr>
<tr>
<td>Cord formation</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Niacin test</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Nitrate reduction test</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Growth on p-nitrobenzoic acid (PNB)</td>
<td>500 µg/ml</td>
<td></td>
</tr>
</tbody>
</table>
8. New Technologies in HIV Diagnosis and ART Monitoring

High costs of assays used in diagnosis and monitoring is one of the concerns for HIV control and treatment programmes. Newer technologies providing economical assays are very important for such programmes. The specific areas where such assays will be needed are:

- HIV diagnosis
- CD4 count estimation
- Plasma viral load determination

The new technologies must be properly validated before applying them in resource poor settings and should follow strict quality control regimen in the programme.

**HIV Diagnosis**

Conventional HIV diagnostic methods have disadvantages because of the need for cold chain for sample transport and storage as well as for conducting invasive procedure. Some of the newer approaches obviate these shortcomings.

**Tests on samples other than blood (saliva and urine):** Commercial tests available for the detection of anti-HIV antibodies in urine and saliva specimens have shown promising results. However, no approved confirmatory tests are available for urine samples. The tests that use saliva samples are more expensive than blood tests.

**Tests using dried blood spot:** Antibody detection on dried blood spots has been employed in field surveys in infections other than HIV. The
advantages include stability at room temperature obviating the need for cold chain, suitability for community-based surveys and adaptability for collection of large number of samples. It can be adopted for confirmation in Western Blot. However, No data on borderline samples/recently infected individuals with probable low titer antibody are available. The system has still to undergo vigorous quality assessment. Some of the commercially available kits for antibody detection may not be suitable for this strategy.

**CD4 Count Estimation**

Consistency in the CD4 counts (for adults) and CD4/CD8 monitoring (for children) is the essence in monitoring disease progression in HIV infection, to decide when to start treatments and to monitor response to ARV treatment (in the absence of viral load) and decide on when it is safe to stop prophylaxis for opportunistic infections.

Flow cytometry is a widely used method for estimation of CD4 counts. Flow cytometer and reagents are expensive and hence cause concern in the developing countries. Cheaper flow based assays are likely to be available very soon.

**Newer Techniques for Low-cost Approach to Estimate CD4 Counts**

**Economic flow cytometry**

Combined use of CD4 and CD45 conjugated antibodies (panleucogating) has been found to be workable and cost-effective.

**Modified flow cytometry**

Cyflow from Partec: The system works on volumetric method i.e. known amount of blood with a single antibody reagent. It can also be run on solar panel and car batteries and hence may be used in remote areas. The methodology is simple to carry out based on a single platform method with single antibody reagent and ten minutes incubation. The system showed good correlation with the CD4 counts obtained by conventional flow cytometry. However, an experienced technician is required for accurate measurement.
The CyFlow capital equipment cost is < US$20 000 and the cost per test < US$2.

Guava technology: A single platform system that uses CD3 antibodies to measure T lymphocytes and CD4 antibodies to estimate absolute T cells expressing CD4. The system showed good correlation with conventional flow cytometry and is easy to operate. It uses smaller blood volume. It requires very minimal infrastructure facilities and it is easy to train the technologists to perform the test. The cost per test is around US$ 2 to 4. However, the equipment costs about US$ 40 000.

Microscope-based CD4 counting systems

Microbead system (Dyna Beads) uses two types of beads. The first bead removes monocytes from the sample and the second (CD4) estimates CD4 cells that get stained with acridine orange to make the cell nuclei visible for counting under a fluorescent microscope. The initial cost of equipment for a fluorescence microscope is low (US$10 000) with a running cost of US$ 4 to 5 per test. A modified DynaBeads system with an alternate stain for the cells can be used with a light microscope.

The Cytosphere system (Beckman Coulter) has the advantage of ease of use by those haematology technicians who are familiar with the shapes of cells. Here the monocytes are not removed but appear different under the microscope, so the bead-covered CD4+ T cells can be counted.

Of the two systems, Dynabead has been found to be more accurate and reproducible. However, these methods are manual and labour intensive. To scale these up to match expanding access to ART may prove a challenge. The automation by addition of image analysis software would increase the potential of its use in ART monitoring. The system could be cheaper than other alternatives and will be useful in small settings if it is backed up with flow cytometry for quality assurance.
**ELISA-based counting systems (Capcellia ELISA and TRAx and Zymmune)**

The ELISA systems measure CD4 protein in the lysed whole blood. The system could be automated easily and can be used on a large number of samples. The initial cost is US$ 5000. These systems have shown some promise but still need to be validated on larger scale.

**CD4 count estimation from dried blood spots**

The technique uses an antibody “sandwich” to capture and detect CD4 proteins in the sample. As it stands, it does not give a close match to CD4 T-lymphocytes measured by flow cytometry, and the discrepancy (an overestimation of CD4 T-cells) increases as the actual CD4 count declines.

**Viral Load Measurement**

Measurement of plasma virus load is currently being used for monitoring the progression of HIV infection as well as to monitor the efficacy of anti-retroviral treatment. Current methods of determining of plasma virus load include quantitative RT-PCR, branched DNA technology and NASBA. These technologies are expensive and may not be affordable for programmes in developing countries. A few alternative approaches that are under investigation are mentioned below.

- **Real time PCR:** The technique can be used as a modified cost-effective approach for viral load measurement with around 30 to 50% cost reduction. However, the methodology is still under validation. Few commercial kits are available for real time PCR application for determining plasma virus load. On validation, they may provide cheaper option.

- **Viral load measurement on dried blood spot:** Dried blood spots and dried plasma spots have been evaluated for viral load measurements in Zambia on 51 HIV infected individuals. The viral load estimation was performed by nucleic acid amplification (NASBA) technique with good correlation standard assay. However, continuing research on DBS is needed to better understand the effects of variables such as drying time, humidity and temperature on RNA stability.
• Alternative Approach: P24 Quantikin ELISA from Perkin Elmer that can quantitate p24 in the serum or plasma of HIV-infected individuals has been claimed to correlate well with the plasma viral load. It could be used as an alternative test for viral load for monitoring ART. The system requires validation for non-B subtypes.

Table 8.1. **Newer technologies in HIV diagnosis and ART monitoring**

<table>
<thead>
<tr>
<th>HIV Diagnosis</th>
<th>Type of test</th>
<th>Principle</th>
<th>Remarks</th>
<th>Comparison with Gold standard</th>
</tr>
</thead>
</table>
| antibody detection assays | Detection of antibodies in saliva and urine | No FDA approved kit for urine testing  
Saliva testing may be costly | Good                          |
| Antibody detection assays | Detection of antibodies in fluid eluted from dried blood spot | Convenient sample collection and transport  
Cost-effective | Good                          |
| CD4 count estimation | Flow cytometry-based assays                      | Panleucogating/ A combination of CD4 and CD45 antibodies | Cost-effective without compromising quality | Good                          |
| CD4 count estimation | volumetric method (Partec)                      | Cheap (2 US$ per test)  
Could be useful in field  
Requires trained personnel | Good                          |
| CD4 count estimation | Guava technology  
Works on CD3+ lymphocyte gating | Cheap (2 to 4 US$ per test)  
Simple to operate | Good                          |
| Microscope-based assays | Uses Dyna beads to identify CD4 lymphocytes | Might be useful at peripheral centers  
Cost-effective  
However requires fluorescence | Good                          |
<table>
<thead>
<tr>
<th>HIV Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of test</strong></td>
</tr>
<tr>
<td><strong>microscope</strong></td>
</tr>
<tr>
<td><strong>ELISA-based assays</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Plasma Viral Load estimation</strong></td>
</tr>
<tr>
<td>Real time PCR</td>
</tr>
<tr>
<td>Viral load measurement from dried blood spot</td>
</tr>
<tr>
<td>p24 quantitation</td>
</tr>
</tbody>
</table>
9. Laboratory Infrastructure and Quality System

The organization of laboratories in any country is usually a three- or four-tier system with various possible functional linkages between them. There must also be transport and communication facilities between peripheral and intermediate laboratories for referral of samples and patients, procurement of supplies and personal discussion. Laboratory investigations can be established based on the level of the laboratory set-up required for that region, as follows:

Level 1: Peripheral Laboratories

**Functions:** These laboratories provide technical support for the diagnosis and clinical management of HIV-infected individuals (monitoring of HIV and ART). This level of laboratory will perform some simple testing, such as HIV rapid testing, haemoglobin estimation, TB smear examination, cell count (TC and DC), pregnancy testing and basic biochemistry tests which do not require much skills.

**Staffing:** The staff in peripheral laboratories should include at least one microbiologist/pathologist, one technician and one laboratory assistant/attendant.

**Space:** Space available in peripheral laboratories should include at least one laboratory-cum-office/record room (approx 5 metres x 3 metres) and one store-room which can be used for other services also (approx 5 metres x 3 metres).

**Equipment:** Light microscope (binocular) - 1; small refrigerator (165 litre capacity) - 1; Bio-safety centrifuge (maximum RPM 5000) - 1; autoclave - 2; safety spectacles; micropipettes (variable volume 40-200uL) - 2; micropipettes (variable volume 5-40uL) - 2; Bunsen burner with LPG; sample racks; computer with printer - 1; needle destroyer - 1.
Other facilities: Other facilities include prompt laboratory supplies (glass slide, coverslip, staining solutions, microtips, transport media, sterile swabs, vacutainer or syringe, test tubes, sample containers, serological pipettes, Pasteur pipettes, diagnostic kits etc.), work bench (at least 0.5 x 6 metres length of concrete), chairs and cupboards, supply of safe water, stabilized power supply (power cut should not be for more than 2 hours), telephone, waste disposal facilities, PEP availability, Separate sinks for bio-waste and clean in each laboratory area, eye wash stations, fire extinguishers etc.

Level 2: Intermediate Laboratories

Functions: The functions expected to be performed by the intermediate laboratories include support to clinical diagnosis/public health, quality assurance, logistic and technical support and training of staff for peripheral laboratories. These laboratories also serve as links between peripheral laboratories and the state/central laboratory for the following: collection, storage and analysis of data, distribution of reagents, media, preparation of laboratory manuals and standard operative procedures for the functions to be carried out at peripheral as well as intermediate laboratories, purchase of equipment, supervision of peripheral laboratories, to conduct EQA for peripheral laboratories, to take part in EQA organized by state/central laboratories and to send samples to higher/reference laboratories for characterization of isolate/confirmation of diagnosis.

Staffing: One qualified laboratory supervisor/manager (master’s degree in pathology/medical microbiology), three Technical Assistants (undergraduate in biochemistry or microbiology plus DMLT, three Technicians (cum Phlebotomist), one Laboratory attendant-cum-Housekeeper and one Clerk-cum-storekeeper.

Space: Space available in level 2 laboratories should include one room (approx 5 x 5 meters) for microbiology, one room for sterilization, media preparation (approx 3 meters x 3 meters), one room (approx 5 x 5 meters) for serology and biochemistry, one room (approx. 5 x 5 meters) for haematology and immunology, store-room (approx 3 meters x 3 meters), office (approx 3 meters x 5 meters) and one room for staff resting/dining (approx 3 meters x 3 meters).

Equipment: Light microscope (binocular) – 2, biosafety cabinet (class II) - 2, autoclave – 2, incubator - 2, hot air oven - 1, water bath - 2, VDRL shaker -
1, autoanalyser - 1 and at least one semi-autoanalyser as a back-up, computer with printer - 3, refrigerators (>200 litre capacity) - 3, bio-safety centrifuge (the maximum RPM 5000) - 2, weighing balance - 1, pH meter - 1, ELISA washer -1, ELISA reader - 1, flow cytometer (single or dual platform) - 1, Western blot rocker - 1, hematolology analyser (3 part) - 1, deep freezer (-20°C or colder) - 1, inspissator - 1, distilled water apparatus - 1, safety spectacles/protective glass shields, micropipettes (variable volume 200uL - 1000uL), micropipettes (variable volume 40-200uL), micropipettes (variable volume 5-40uL), needle destroyer, Bunsen burners with LPG, laminar flow hood (biosafety cabinet class II) and sample racks.

Other facilities: Other facilities include prompt laboratory supplies including plastic wares, glasswares and diagnostic kits, work bench (at least 0.5 x 6 meters length of concrete with granite table top) in each laboratory area, Air-conditioned laboratory rooms, sufficient chairs and cupboards, supply of safe water, stabilized power supply with battery back-up for at least 4 hours (power cut should not be for more than 2 hours), telephone, internet, waste disposal facilities, PEP availability, readily available technical supports for all the equipment, separate sinks for bio-waste and clean in each laboratory area, eye wash stations, fire extinguishers, etc.

Level 3: Central or National Laboratories

Functions: The National laboratory shall provide technical support to intermediate and peripheral laboratories by training, maintenance of laboratory QA/QC, purchase of equipment, validation and selection of diagnostic kits, preparation of testing algorithms, supervision, preparation of laboratory manuals and standard operative procedures for the functions to be carried out at all three levels of laboratories, dissemination of newsletter, to conduct EQA and characterize of isolate/confirm the diagnosis.

These laboratories should have more facilities than those for the Intermediate level plus additional facilities such as cell culture facility, facilities to carry out techniques like PCR, viral load estimation. The laboratory should also have a flow cytometer to run a QA program for intermediate laboratory where an alternate system for CD4 count estimation might be in use. This level of laboratories should be participating in international EQAS programme, conducting continuing education, workshops and hands-on training programme.
The functions of the laboratories at various levels have been described in Chapter 1.

Health services are utilizing laboratories more extensively now than ever before. Laboratories play an important role in the diagnosis of HIV infection as well as monitoring of anti-retroviral treatment. The demand for quality results from laboratories has been echoed by all the health care professionals caring for HIV-positive individuals. Unreliable laboratory results are known to have serious consequences for the health of the individual as well as the community. It is important to have a system of networking peripheral with regional and central laboratories of a country in order to facilitate quick and accurate processing and testing of specimens collected from patients, quick dissemination of information to the peripheral levels as well as to run a quality assurance programme. One possible way of networking of laboratories is shown in Fig 9.1.

Figure 9.1 Possible networking of laboratories

Quality System in the Laboratory

In any laboratory dealing with HIV, quality is an essential element to ensure consistency, reproducibility, traceability and efficacy of products or services. In the context of HIV-related laboratory services also, quality assumes great importance since the physician utilizes the report generated in the laboratory for the benefit of the patient and the community. A quality laboratory report thus helps the physician to establish proper diagnosis rapidly and supports better health care for the patient. Apart from providing accurate results, maintaining quality in laboratory services also helps in generating confidence among patients in the health care system, creating a good reputation for the
laboratory, reducing costs by avoiding repetition of tests, sustains motivation in laboratory staff, helps in the accreditation of the laboratory and above all prevents legal suits and associated complications. In recent times, quality has been considered to be synonymous with consistency which denotes providing the same product or service time after time thus making the outcome more predictable.

The external quality assessment scheme compares the performance of different testing sites and is a challenge to other components of the quality assurance system (internal quality control). This assessment is achieved through processing of specimens of undisclosed but known contents, and it measures the accuracy of the results. Quality is considered the degree of congruence between expectation and realization. In simpler words, it is the matching of what you want with what you get i.e. expectations versus fulfilment. In recent times quality has been considered to be synonymous with consistency which denotes providing the same product or service time after time thus making the outcome more predictable. In the context of health laboratory services, the product denotes the material

**Key Elements of a Quality System**

A quality system has the following key elements:

- Organizational management and structure
- Training
- Referential (quality) standards
- Documentation
- Monitoring and evaluation
- Assessment of quality system

**Organizational Management and Structure**

The overall responsibility for the design, implementation, maintenance and improvements in a quality system rests with the laboratory management.

Quality assurance is the responsibility of all the staff members of the organization. However, the top management needs to make a firm
commitment to ensure quality and allocate adequate resources. A quality policy reflects the intention and commitment of the organization to attain quality. The policy can be translated into implementation through a quality plan, which, along with the policy, needs to be documented in the form of a quality manual.

Laboratory management delegates responsibility and authority to appropriate individuals who are directly responsible for implementing the quality policy and quality system. It makes available to them adequate resources to efficiently discharge their duties. The inter-relationship between various staff members and their job descriptions are decided by the management.

**Training**

The quality system is only as good as the staff that actually works with it. No matter how good the quality system is on paper, if the theory cannot be translated into practice, quality cannot be achieved. Staff may need to be trained and this training must also include an understanding of why quality is important. Training should be competency based and must be followed by post-training support to enable staff to maintain high standards.

**Referential (quality) Standards**

The referential standards are an integral part of the quality system. These aim at ensuring safety and consistency of the procedures. These need to be followed to meet the regulatory requirements as well as to monitor the functioning of the laboratory.

Both management and technical standards need to be followed to ensure quality. These must also conform to the local laws.

**Documentation**

Documentation is a record of any information or instructions including policy statements, quality manuals, procedures, specifications, calibration tables, standard operative procedures for maintenance and calibration of equipment, reports, job descriptions, documents of external origin such as regulations, standards and examination procedures etc. These would include information on various media, including the electronic media.
The quality system of a laboratory shall define, document and maintain procedures to control all documents and information (from internal and external resources). The current version of relevant documents shall be available at all locations where operations needed for effective functioning of the quality system are performed.

Monitoring and Evaluation

The laboratory management must develop and implement quality indicators to systematically monitor and evaluate the laboratory’s contribution to patient care. When the programme identifies opportunities for improvements within the system, the laboratory management needs to take appropriate steps to address them. Error management must be vigorously implemented.

Besides, quality assessment through internal and external audits and participation in external quality assessments schemes should also serve to improve the quality.

Assessment of Quality System

A quality system can be assessed either through an onsite inspection (audit) or by sending known but undisclosed material to the laboratories for testing (quality assessment scheme). The latter can be done within an institute by internal staff (internal quality assessment scheme- IQAS) or through an external agency (external quality assessment scheme- EQAS).

Good Laboratory Practice

Good laboratory practice (GLP) indicates the performance of all the activities of the laboratory in the best possible way so that the results obtained are of the highest possible accuracy and reliable. GLP encompasses various factors as follows:

Laboratory infrastructure

Laboratory should be of suitable size and location and meet biosafety requirements. The facilities should be spacious enough to avoid problems such as overcrowding, cross contamination and cramped working conditions. Utilities (water, electricity, etc.) must be adequate and stable.
**Human resource**

The laboratory should be manned by qualified and trained staff. Specific training records regarding the procedures to be carried out by the specific technicians should be available. The responsibilities of all personnel should be defined and recorded in job descriptions. The number of personnel must be sufficient to perform the tasks required in a timely manner.

**Equipment and reagents**

- All equipment must be in working condition. A strict programme of validation, calibration and maintenance should be in place.
- All equipment should be suitable for its intended use, and it should be properly calibrated and maintained to ensure accurate performance. Records of repairs and routine maintenance are essential.
- Back-up for vital equipment should be available whenever possible as well as back-up in the event of services failures, such as power cuts.

**Documentation**

- Routine procedures must be described in written Standard Operating Procedures (SOPs). They must be reviewed regularly and modified, if necessary. The modified versions should be signed and dated by the laboratory director. The recent most version of SOPs should be available directly at the work place. The old versions should be archived in the laboratory and should be archived if required.
- The records must be stored for long periods of time but be available for prompt retrieval, safe archiving of all records must be ensured. Archiving of the source documents and other essential documents must be such that data are kept in an integer state and can neither be lost nor altered to achieve this goal.
- Records of usage, maintenance and calibration should be kept in the laboratory and should be routinely monitored. Reports of the tests should be released only after proper scrutiny and documentation of the scrutiny with the signature and date by the lab-supervisor.
**General practices**

- Proper collection and transportation of bio-specimens in appropriate condition to testing laboratory.
- Collection and storage under conditions which prevent deterioration of the sample before the performance of test.
- Accurate performance of test.
- Maintaining internal quality control and quality assurance system.
- Participating in the External Quality Assessment Scheme (EQAS).
- Delivery of reports to the correct destination with shortest turn around time (TAT).
- Availability of SOP for all the procedures carried out in the laboratory, monitoring and documentation of strict adherence to SOP.

**Bio-safety practices**

Safety procedures include laboratory protection of the material to be tested, environment and the staff. Personal and laboratory safety can be achieved only by informed, trained responsible individuals through the application of standard precautions.

Standard precautions are simple infection control measures that reduce the risk of transmission of pathogens through exposure to blood or body fluids. The laboratory personnel should be trained in safe handling of the clinical specimen and disposal of bio-waste materials. Documentation of biosafety training for laboratory staff is essential including records on vaccinations such as hepatitis B vaccination. SOP for biosafety procedures should be in place. The following are the recommendations for the safe practice in the laboratory and for better bio-waste management:

- Never eat, drink or apply cosmetics in a laboratory.
- Vaccinate laboratory personnel against hepatitis B.
- Use gloves as a barrier protection during phlebotomy.
• Use barrier protection with gloves, gowns/aprons, face shield, deflector mask, goggles whenever splash of infectious fluid are expected.

• Use biosafety centrifuges for sample processing.

• Use biosafety cabinet while working on specimens which may produce aerosols.

• Use puncture-proof containers for disposing of sharps and these must be as close to the point of use as possible

• Dispose of sharps yourself immediately.

• Do not recap, bend or break used needles – but recapping may be done with single-hand method.

• Carefully place used plastic syringes, needles and sharps in the containers, then disinfect by chemical or physical methods i.e. boiling or autoclaving before disposing into Incinerator.

• Replace the sharps disposal container by a new one when it is three quarters full.

• Never pass used sharps directly from one person to another.

• Keep all sharps and sharp disposal containers out of the reach of children.

• Do not touch blood spills with your bare hands; cover blood with a 0.5-1% sodium hypochlorite solution (household bleach); leave it for at least 15-30 minutes; cover with gauze, cotton or sponge and finally wipe away with gloved hands.

• If spills involve any broken glassware, it must be picked up using a mechanical means, such as a brush and dustpan, or forceps. In cases where the absorbent becomes saturated with blood and bleach, the spill clean up materials should be autoclaved prior to being disposed of in the normal trash.

• Label the bio-waste materials container with the “Biohazard Label” (Figure 9.2).
• Segregate waste into dry solid waste and liquid waste.

• Package all waste to prevent spills, leaks or breaks during transportation.

• Before disposing, pre-treat the waste.

• Liquid waste such as human blood and blood components such as serum, plasma, etc., and human body fluids should be considered as potentially infectious. Before disposing, this liquid waste should be decontaminated by adding a sufficient volume of sodium hypochlorite to obtain a final concentration of at least 1%. A 30 minute exposure to 1% sodium hypochlorite may be sufficient to ensure effective decontamination. Commercial liquid household bleach typically contains a concentration of 5.25% sodium hypochlorite. A 1:5 dilution of household bleach will produce a 1% sodium hypochlorite solution. After decontamination, the waste could be disposed in the sewer.

• Solid biohazardous waste must be pretreated by decontamination (such as autoclaving) before disposal. All waste must be collected in biohazard bags or closed, leak-proof, labelled containers, to prevent spillage or protrusion of contents during handling or transport.

• Color-coded containers (red) marked with the universal biohazard symbol should be used. Plastic liner should be used inside bio-waste container.

Figure 9.2 Biohazard label.
• Disinfect (with 0.5% sodium hypochlorite) work places when procedures are completed or after any spill of blood or other potentially infectious material in the workplace.

Health care workers and laboratory staff are normally at very low risk of acquiring HIV infection during management of HIV-infected patients. In prospective studies, the average risk of HIV transmission after a percutaneous exposure to HIV-infected blood has been estimated to be approximately 0.3% and after a mucous membrane exposure, approximately 0.09%. The risk of infection varies with

• type of exposure (superficial or deep injury)
• the amount of blood involved in the exposure
• amount of virus in patient’s blood at the time of exposure
• Whether post-exposure prophylaxis (PEP) was taken within the recommended time (not later than 36 hours after exposure) as shown in Table 10.1.

It is necessary to have a comprehensive programme in place to deal with anticipated accidental exposure. Prevention is the mainstay of strategy to avoid occupational exposure to blood / body fluids. Adequate infrastructure and training should be provided in the settings.

What to do after a needle stick injury?

• Wash the injured site thoroughly with soap and water (antiseptics may be used).
• Administer post-exposure prophylaxis (PEP) for HIV, based on institutional policy.
• If as a result of a laboratory accident the skin is broken the wound should be cleaned and irrigated with a mild disinfectant such as chlorhexidine with cetrimide (eg. Savlon).

The person should be provided with pretest counselling and anti-retroviral drug prophylaxis started as per the physician’s recommendation. Before starting prophylaxis, a sample should be collected for baseline anti-HIV antibody estimation. Sample should be tested for anti-HIV antibodies immediately after the exposure to know the HIV status. In case the sample tests positive, the individual is referred to the clinician for management, as a
case of HIV infection. In case the sample tests negative, a second sample is collected at 6 weeks and third at 12 weeks after the exposure and tested for HIV antibodies. Post-test counselling should be done in all cases. During the follow-up period, especially the first 6-12 weeks, when most infected persons are expected to show signs of infection, the recommendations for preventing transmission of HIV are to be followed by healthcare workers. These include refraining from blood, semen, organ donation and abstaining from sexual intercourse. In case sexual intercourse is undertaken, a latex condom must be used correctly and consistently. In addition, women should not breast-feed their infants during the follow-up period after exposure to prevent exposing their infants to HIV in breast milk.

The technical personnel should be familiar with the safety precautionary measures.

Table 9.1. **Recommendations procedures for post-exposure management.**

<table>
<thead>
<tr>
<th>Infectious agent</th>
<th>Postexposure prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>Antiretroviral therapy</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B immune globulin (HBIG) and/or hepatitis B vaccine</td>
</tr>
<tr>
<td>HCV</td>
<td>Immune globulin and antiviral agents (e.g., Interferon with or without Ribavirin)</td>
</tr>
</tbody>
</table>

**Drugs recommended for HIV post-exposure prophylaxis**

It is recommended that Zidovudine (ZDV) 300mg bid and Lamivudine (3TC) 150 mg bid be used in combination for a period of four weeks. In selected cases, Indinavir (or one of the other protease inhibitors) can be used as per PEP guidelines. The drugs are usually well tolerated except for transient nausea, vomiting, diarrhoea, tiredness or headache. An emergency supply of these drugs should be available in all hospitals dealing with potentially infected material.
Suggested Further Reading


Annex 1

SUGGESTED SOURCES OF AVAILABILITY OF LABORATORY EQUIPMENT AND SUPPLIES

The following web-sites are suggested only for information and not recommended by WHO. Programme managers are encouraged to get more information from other sources also.

www.axygen.com; www.bio-rad.com; www.bd.com;
www.beckmancoulter.com; www.abbdiagnostics.com;
www.biomerieux.com; www.tranasia.co.in; www.sysmex.com
www.ambalayellowpages.com/5.htm; www.kendro.com;
www.dmoz.org/Science/Instruments_and_Supplies/Laboratory_Equipment;
www.wheecon.com; www.roche.com; www.guavatechnologies.com;
www.span.co.in; www.orthoclinical.com; www.labindia.com;
www.catalogs.indiamart.com/category/scientific-instruments.html;
www.ifcc.org/ejifcc/vol15no1/150102200401n.htm;
www.trade-india.com/dyn/gdh/catalog/hp/1919/catalog.htm;
www.trade-india.com/dyn/gdh/eyp/Industrial_Supplies/Laboratory_Glassware_and_Equipment/;
www.noor-scientific.com/bio/thermo.htm;
www.indiayellowpagesonline.com/a-z/l/2.htm;
www.biowire.com; www.labsafety.com; www.labfurnishers.com;
www.remelinc.com/products/clinical/laboratory_supplies.cfm;
www.who.amds.com

Sources of EQAS

www.who.int/eht/Main_areas_of_work/DIL/Lab_Tech/External_Quality_Assessment.htm www.aab.org

Bio-specimen Shipping Training (IATA)

www.worldcourier.com; www.saftpak.com
<table>
<thead>
<tr>
<th>Lab. Test</th>
<th>Specimen</th>
<th>Recommended Activities</th>
<th>Specimen integrity at RT</th>
<th>Short-term storage</th>
<th>Long term storage</th>
<th>Factors associated with erroneous results</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV testing and other serology</td>
<td>Serum</td>
<td>-</td>
<td>-</td>
<td>Serum should be separated within 4 hours if stored at RT and 24 hours if stored at 2-8°C</td>
<td>-20°C or colder</td>
<td>Hemolysis, hyperlipemic, contamination</td>
</tr>
<tr>
<td>CD4</td>
<td>Whole blood</td>
<td>*</td>
<td>*K3 EDTA or heparin</td>
<td>Preferably &lt;25 ± 2°C</td>
<td>-</td>
<td>Clot hemolysis, storage more than recommended contamination</td>
</tr>
<tr>
<td>Viral load</td>
<td>Plasma</td>
<td></td>
<td>K3 EDTA</td>
<td>Preferably &lt;25 ± 2°C Plasma should be separated within 6 hours</td>
<td>-70°C or colder</td>
<td>Use of unsterile storage vials, fluctuation in freezer temperature. More than 3 freeze-thaw cycle</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>Whole blood</td>
<td></td>
<td>K3 EDTA</td>
<td>Preferably &lt;25 ± 2°C</td>
<td>-</td>
<td>Clot, Hemolysis</td>
</tr>
<tr>
<td>Lab. Test</td>
<td>Specimen</td>
<td>Recommended Activities</td>
<td>Specimen integrity at RT</td>
<td>Short-term storage</td>
<td>Long-term storage</td>
<td>Factors associated with erroneous results</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>------------------------------------------</td>
<td>--------------------</td>
<td>-------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Blood chemistry sugar, lactate</td>
<td>Plasma</td>
<td>Sodium Fluoride</td>
<td>Preferably &lt;25 ±2°C</td>
<td>At 2-8°C for same day testing</td>
<td>-20°C or colder</td>
<td>Clot, delayed specimen processing. For lactate fasting specimen is recommended.</td>
</tr>
<tr>
<td>Blood chemistry Serum electrolytes</td>
<td>Serum</td>
<td></td>
<td>Preferably &lt;25 ±2°C</td>
<td>At 2-8°C for same day testing</td>
<td>-20°C or colder</td>
<td>Delayed specimen processing.</td>
</tr>
<tr>
<td>Blood chemistry LFT, KFT, etc.,</td>
<td>Serum</td>
<td></td>
<td>Preferably &lt;25 ±2°C</td>
<td>At 2-8°C for same day testing</td>
<td>-20°C or colder</td>
<td>Hemolysis.</td>
</tr>
<tr>
<td>Pregnancy Testing</td>
<td>Urine or Serum</td>
<td></td>
<td>Preferably &lt;25 ±2°C</td>
<td>At 2-8°C for same day testing</td>
<td>-</td>
<td>Early morning urine is recommended.</td>
</tr>
<tr>
<td>OI diagnosis</td>
<td>Sputum CSF, serum, swabs, stool etc.</td>
<td></td>
<td>Preferably &lt;25 ±2°C</td>
<td>At 2-8°C for same day testing</td>
<td>-</td>
<td>Improperly collected, transported specimen.</td>
</tr>
</tbody>
</table>
Annex 3

PROCEDURES CARRYING POTENTIAL RISKS OF HIV, HBV AND OTHER BLOODBORNE AGENTS.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Person at risk</th>
<th>Mode of transmission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collection of blood sample</td>
<td>Patient</td>
<td>Contaminated needle&lt;br&gt;Contaminated hand or gloves of health worker&lt;br&gt;Skin puncture by needle or broken specimen container&lt;br&gt;Contamination of hands by blood</td>
</tr>
<tr>
<td>Transport of specimens (within laboratory)</td>
<td>Laboratory personnel&lt;br&gt;Transport worker</td>
<td>Contaminated exterior of specimens container&lt;br&gt;Broken container&lt;br&gt;Spill or splash of specimen</td>
</tr>
<tr>
<td>HIV serology and virology</td>
<td>Laboratory personnel</td>
<td>Skin puncture or contamination of skin or Mucous membrane&lt;br&gt;Contaminated exterior of specimen container&lt;br&gt;Contaminated work surface&lt;br&gt;Spill or splash of specimen&lt;br&gt;Broken specimen container&lt;br&gt;Perforated gloves</td>
</tr>
<tr>
<td>Cleaning and maintenance</td>
<td>Laboratory personnel&lt;br&gt;Support staff</td>
<td>Skin puncture or skin contamination&lt;br&gt;Spills or splashes&lt;br&gt;Contaminated work surface</td>
</tr>
<tr>
<td>Waste disposal</td>
<td>Laboratory personnel&lt;br&gt;Support staff&lt;br&gt;Transport worker</td>
<td>Contact with contaminated waste&lt;br&gt;Puncture wounds and cuts</td>
</tr>
<tr>
<td>Shipment of specimens (to other centers)</td>
<td>Public transport worker&lt;br&gt;Postal worker&lt;br&gt;Public</td>
<td>Broken or leaking specimen containers and packages</td>
</tr>
</tbody>
</table>
Annex 4

CONTRIBUTORS AND REVIEWERS

Dr Suniti Solomon, M.D.
Director, YRG Centre for AIDS Research and Education(YRG CARE),
Voluntary Health Services Hospital Campus, Taramani,
Chennai - 600 113
India.
E-mail: suniti@yrgcare.org

Dr Kovit Pattanapanyasat, Ph.D.
Center of Excellence for Flow cytometry, Faculty of Medicine
Siriraj Hospital
Mahidol University
Bangkok
Thailand.
E-mail: grkpy@mahidol.ac.th

Dr Ramesh Paranjape, Ph.D.
Officer-In-Charge
National AIDS Research Institute(NARI)
G-73, M.I.D.C
Bhosari
Pune- 411 026, India.
E-mail: rparanjape@nariindia.org

Dr V. Ravi, M.D.
Professor and Head,
Department of Neurovirology
National Institute of Mental Health and Neurosciences (NIMHANS)
Bangalore - 560029, India.
E-mail: vrag@nimbhans.kar.nic.in

Dr G. Sridharan, Ph.D.
Professor and Head
Department of Clinical Virology
Christian Medical College Hospital
Vellore - 632 004
India
E-mail: g_sridharan@yahoo.com

Dr Madhuri Thakar, Ph.D.
Senior Research Officer
Department of Immunology
National AIDS Research Institute (NARI)
G-73, M.I.D.C.,Bhosari
Pune- 411 026,
India.
Email: madhurithakar@hotmail.com

Dr Soumya Saminathan, M.D.
Director, Division of AIDS
Tuberculosis Research Centre
Chetpet, Chennai,
India.
E-mail: doctor_soumya@yahoo.com

Dr P.Balakrishnan, Ph.D.
Laboratory Manager for NIH funded Projects,
Associate Professor of Microbiology,
YRG Centre for AIDS Research & Education,
Voluntary Health Services Hospital Campus,
Taramani, Chennai - 600 113,
India.
E-mail: bala@yrgcare.org

Dr N.Kumarasamy, MBBS, Ph.D.
Chief Medical Officer,
YRG Centre for AIDS Research and Education (YRG CARE),
Voluntary Health Services Hospital Campus,
Taramani, Chennai-600 113,
India.
E-mail: kumarasamy@yrgcare.org
Dr Rajesh Bhatia, M.D.
STP, Blood safety and Clinical Technology
WHO/South-East Asia Regional Office
IP Estate, Ring Road
New Delhi 110 002
India.
00-91-11-23370804 Extn 26504.
E-mail: bhatiaraj@whosea.org

Dr Sirirat Likanonsakul
Chief, Immunology and Virology Laboratory
Bamrasnaradura Institute
126 Tiwanon Road
Nonthaburi 11000, Thailand
E-mail: siratlik@health.moph.go.th

Ms Monthasawat Rattanasrithong,
Chief of Medical Technology Section
Bamrasnaradura Institute
126 Tiwanon Road
Nonthaburi 11000, Thailand

Dr Renu Garg,
STP-HIV,
WHO/SEARO,
New Delhi 110002, India
gargr@whosea.org

Reviews
Dr Bharat Ramratnam, M.D.
Laboratory of Retrovirology
Division of Infectious Diseases
Brown Medical School
Providence, RI 02903,
USA
E-mail: BRamratnam@Lifespan.org

Ms Monthasawat Rattanasrithong,
Chief of Medical Technology Section
Bamrasnaradura Institute
126 Tiwanon Road
Nonthaburi 11000, Thailand

Dr Renu Garg,
STP-HIV,
WHO/SEARO,
New Delhi 110002, India
gargr@whosea.org